Biogen Upgraded at UBS on Alzheimer’s Clinical Trial Progress –

June 19, 2017 by  
Filed under Alzheimers News

Sponsored By
Biogen Upgraded at UBS on Alzheimer's Clinical Trial Progress
UBS Analyst Carter Gould said the Cambridge, MA-based biopharmaceutical company's risk/reward profile has improved due to recent progress with their Aducanumab drug to treat Alzheimer's. Market competition for Biogen's spinal muscular atrophy …

and more »

More Info: Click here

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!